Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Chemotherapy of first line "reinforced" for cancers of the colonist and the rectum with hepatic and/or pulmonary metastases potentially resecables: Strong association FOLFIRI and ERBITUX.

Trial Profile

Chemotherapy of first line "reinforced" for cancers of the colonist and the rectum with hepatic and/or pulmonary metastases potentially resecables: Strong association FOLFIRI and ERBITUX.

Completed
Phase of Trial: Phase II

Latest Information Update: 13 Jun 2013

At a glance

  • Drugs Cetuximab (Primary) ; Fluorouracil; Folinic acid; Irinotecan
  • Indications Cancer metastases; Colorectal cancer
  • Focus Therapeutic Use
  • Acronyms ERBIFORT
  • Most Recent Events

    • 06 Nov 2012 Planned End Date (8 Jul 2012) added as reported by European Clinical Trials Database record.
    • 07 Aug 2012 Additional lead trial centre added as reported by European Clinical Trials Database record.
    • 04 Jul 2012 Merck KGaA and Pfizer added as associations as reported in the European Clinical Trials Database record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top